News

ODU, EVMS, Sentara Name Partnership Executive Director

Kevin Leslie has been named executive director of the new Hampton Roads Biomedical Research Consortium (HRBRC), a partnership between Old Dominion University, Eastern Virginia Medical School (EVMS) and Sentara Healthcare.

Recently approved by Gov. Ralph Northam and the General Assembly, the HRBRC aims to strengthen the relationship among the three institutions and to jump start more research collaboration as well as to ultimately generate health-care improvements in Hampton Roads, making it more efficient and less expensive.

“The state has commissioned a study to recommend the optimal structure for our partnership. But for now, the consortium’s first order of business is to mine the region’s vast collection of health-care data – stripped of personal information,” said Morris Foster, Old Dominion’s vice president for research who helped establish the framework for the consortium. “The resulting algorithms and applications could produce extensive benefits for our region, including wearable devices to monitor health and more pinpointed recommendations for patients.”

Leslie was previously the associate director of VCU Ventures, a division at Virginia Commonwealth University that helps faculty and staff launch startup companies with an eye to innovation in health care. He received his Ph.D. in biophysics from VCU and has worked as a senior scientist in the private sector.

“Kevin knows the biotech ecosystem in the commonwealth, and he’s well-versed in sources of funding opportunities, both on the public and private sides,” Foster said. “Under his direction, the consortium stands poised to build the biotech sector in Hampton Roads and catalyze more innovation.”

Dr. Jordan Asher, Sentara’s chief physician executive, expressed his appreciation for the commonwealth’s support and added: “We are excited to collaborate with ODU and EVMS in this new endeavor to advance research in the Hampton Roads region that will improve the health of our communities.”

“We welcome Kevin to the region and are excited to collaborate with him and our partners in the HRBRC to advance biohealth development and innovation,” said William Wasilenko, vice dean for research at EVMS.

Leslie believes the region as a whole could see a big economic-development boost.

“The HRBRC embodies what drives and excites me: the challenges of a startup, the pursuit of health equity, community building and working with diverse and talented people,” Leslie said. “The foundational pieces of a world-class pipeline are in place. Now, we finally have the opportunity to coordinate them in earnest.

“We’re going to advance science and medicine while holistically strengthening Hampton Roads, and I’m honored to be a part of it.”

According to Foster, Old Dominion’s faculty will benefit from increased opportunities for collaboration with colleagues at EVMS and Sentara and will become more competitive for NIH grants.

“Graduate students will also gain valuable experience in projects that will strengthen their dissertations and their scientific potential after they leave ODU,” he said.

Recent News

03/28/2024

ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases,  announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure

03/28/2024

AMPEL BioSolutions’ Lupus Test Launches to Predict Flares & Drug Targets

AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus.  Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI. The LuGENE® lab test is now launching at

03/27/2024

Shaping Tomorrow’s Innovators: LifeNet Health’s Educational Partnership Ignites Student Passion in Life Science

LifeNet Health, a global leader in regenerative medicine, recently collaborated with AP biology students at Landstown High School to offer hands‐on learning experiences with human tissue and cellular solutions. This initiative is part of the Life Sciences Virginia pilot program, which aims to foster interest in life science careers among students and cultivate a talent